Discovery of a novel 4-pyridyl SLC-0111 analog targeting tumor-associated carbonic anhydrase isoform IX through...

Area of Science:

• Oncology
• Biochemistry
• Medicinal Chemistry

Background:

• Carbonic anhydrase IX (CA IX) is a tumor-associated enzyme crucial for cancer progression and survival.
• Selective CA IX inhibitors, such as SLC-0111, demonstrate therapeutic potential in cancer treatment.
• Developing novel analogs with enhanced efficacy is essential for advancing cancer therapy.

Purpose of the Study:

• To synthesize and characterize a novel 4-pyridyl analog (Pyr) of SLC-0111.
• To evaluate the anticancer activity and mechanism of action of Pyr.
• To assess the drug-like properties and binding affinity of Pyr to CA IX.

Main Methods:

• Synthesis of Pyr using tail-based design and characterization by NMR.
• Cytotoxicity assays against various cancer and normal cell lines.
• Analysis of CA inhibition, cell cycle progression, apoptosis induction, and protein expression.
• Molecular docking and ADMET predictions for binding and pharmacokinetic properties.

Main Results:

• Pyr exhibited selective cytotoxicity against cancer cells and potent inhibition of CA IX.
• Pyr induced G0/G1 cell cycle arrest and apoptosis in cancer cells.
• Modulation of key proteins including p53, Bax, and Bcl-2 was observed.
• Molecular docking confirmed strong binding to CA IX, and ADMET analysis predicted good oral bioavailability.

Conclusions:

• Pyr is a potent and selective inhibitor of CA IX with significant anticancer activity.
• Pyr demonstrates a promising mechanism of action involving cell cycle arrest and apoptosis induction.
• Pyr possesses favorable drug-like properties, supporting its potential as an anticancer therapeutic candidate.